Demonstrating that a follow-on peptide is equivalent to an approved product is harder than for small molecules because the impurity profile is inseparable from the process.
Key Takeaways
- A small-molecule generic is defined by its structure.
- New impurities not present in the reference product require qualification.
- The work is closer to a biosimilar programme than to a conventional generic pathway in terms of effort.
Why sameness is harder
A small-molecule generic is defined by its structure. A peptide’s biological behaviour depends on its impurity profile, counterion, and higher-order state, all of which are process-dependent and cannot be specified by structure alone.
Characterisation burden
Follow-on developers must demonstrate comparability across identity, purity, impurity profile, and biological activity. The analytical package is considerably heavier than for a conventional generic and usually requires orthogonal methods.
For related mechanism work, see peptide blood-brain barrier delivery.
Impurity qualification
New impurities not present in the reference product require qualification. Because deletion sequences and side-reaction products are common in peptide synthesis, this is frequently the most demanding part of the programme.
Immunogenicity comparability
Regulators generally require assessment of immunogenicity risk relative to the reference, given that material-related factors drive immune responses. Aggregate levels and impurity profiles are central to that comparison.
Practical implications
The work is closer to a biosimilar programme than to a conventional generic pathway in terms of effort. Planning and budgeting accordingly avoids the common surprise of underestimating the comparability package.
Experimental Conditions and Practical Setup
Comparability is demonstrated by running the follow-on and reference materials in the same analytical session, using orthogonal methods for identity, purity, and impurity profiling. Side-by-side analysis matters because impurity levels are small and method-to-method differences can otherwise be mistaken for real differences between products.
Comparability package components
| Attribute | Method | Difficulty |
|---|---|---|
| Identity | Mass spectrometry, peptide mapping | Routine |
| Purity and impurity profile | Orthogonal chromatographic methods | Demanding |
| New impurity qualification | Toxicological assessment | Most demanding element |
| Aggregate levels | Size-exclusion, light scattering | Needed for immunogenicity comparison |
Practical Notes for the Bench
- Budget for a comparability package closer to biosimilar than generic.
- Expect impurity qualification to be the most demanding element.
- Characterise aggregate levels explicitly for immunogenicity comparison.
Frequently Asked Questions
Why not simply copy the structure?
Because peptide behaviour depends on process-dependent attributes such as impurity profile and counterion, which structure alone does not define.
What is hardest about the programme?
Usually qualifying new impurities that are absent from the reference product.
Is immunogenicity assessed?
Yes, comparability of immunogenicity risk is generally required, with aggregation and impurities central to the comparison.
Why is this closer to a biosimilar than a generic?
Because a peptide’s behaviour depends on process-dependent attributes such as impurity profile and counterion, which cannot be fully specified by structure alone.
Related Reading
- peptide blood-brain barrier delivery
- peptide therapeutics oncology
- GLP-1 receptor agonist peptides
- disulfide bond verification
- peptide forced degradation
References & Further Reading
- Mattei AE et al. Immunogenicity risk assessment of peptide-related impurities identified in generic teriparatide products. Front Immunol. 2025. PubMed 41445733
- Peptide literature search on PubMed
- Full-text archive at PubMed Central
- FDA guidance documents on peptide drug products
The notes below reflect common laboratory practice and open literature. They are not clinical recommendations, and peptides discussed are research materials unless stated otherwise.
Reviewed by James Okoro, BSc, Laboratory Operations & Documentation.